← 產業報告目錄

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-02-11頁數 404報告編號 MD4740

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global respiratory diagnostics market is projected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5% during the forecast period. The respiratory diagnostics market is driven by many rising impacts with respect to improving cases of respiratory diseases around the world. Innovative technologies in diagnosis, such as molecular diagnostics and advanced imaging solutions, have also improved the accuracy and speed of detection for conditions such as asthma, tuberculosis, or lung cancers. Increased awareness for healthcare providers and patients about the benefits of early diagnosis and more government-sponsored, healthy analysis programs have also served as important fuel sources in the demand for respiratory diagnostic solutions. The COVID-19 pandemic has demonstrated the need for efficient and reliable diagnostics in the management of respiratory infections. However, the market growth is restricted by several factors, including the recent changes in the regulatory framework concerning the approval of new products, their labeling requirements, and complete conformance to quality standards. "Instruments and Devices segment accounted for the largest share in the respiratory diagnostics market." The growing advancements in diagnosis technologies such as diagnostic imaging devices, spirometers, and other respiratory diagnostic instruments have led to such importance in this segment. In addition to this, the rising prevalence of respiratory disease across the globe has greatly increased the demand for advanced and accurate diagnostics tools. The innovations in point-of-care testing devices and portable diagnostic instruments, such as advanced point-of-care testing instruments and portable diagnostic instruments, have enhanced the growth of the Instrument and Devices segment, allowing rapid and accurate respiratory assessment by health professionals. Hence, the above factors are driving respiratory diagnostics market growth in the region. "The Mechanical tests segment accounted for the largest share in the respiratory diagnostics market." Mechanical tests, including tools like spirometers and peak flow meters, are essential for assessing lung function and airflow. The rising incidence of chronic respiratory conditions, such as asthma and COPD, has significantly increased the reliance on these diagnostic methods. Enhanced technological innovations, such as digital spirometry and portable devices, have improved the accuracy, ease of use, and accessibility of mechanical tests, making them more widely adopted in clinical and home settings. Furthermore, the growing emphasis on early diagnosis and continuous monitoring of respiratory health, particularly in managing chronic diseases, is a major driver for the expansion of this segment within the respiratory diagnostics market. "Asthma segment accounted for the largest share in the global respiratory diagnostics market." Increase accession of environmental pollutants, changing lifestyles, and genetic factors contributing to increasing cases in asthma which further necessitates the requirement of advanced diagnostic solutions. Asthma is one of the segments that include diagnostic modalities, pulmonary function tests, imaging techniques, and biomarker assessments, all of which comprise an option for asthma diagnosis and management. However, ongoing research and development initiatives focusing on personalized medicine drive the segment for respiratory diagnostics. "Syndromic segment has accounted for the largest share in the global respiratory diagnostics market." Syndromic segment holds the largest share in the respiratory diagnostics market due to its capabilities of rapid and widespread diagnosis for many pathogens from a single test. The efficiency is very important since in the management of conditions such as influenza and pneumonia, it is vital timeously to identify the causative agent for its effective treatment. Syndromic panels reduce the time in diagnosis and keep for diagnosis, as this promotes early interventions. At the same time, the applications of techniques such as PCR and multiplex assays have improved specificity and access to syndromic panels. Increasing need drives point-of-care testing in hospitals and clinics into adopting syndromic diagnostic solutions. “Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market." While respiratory diseases proliferate, there has been an surged awareness about the need for their early detection. This has in turn led to an increase in the diagnostic procedures carried out in most of these facilities. The segment Hospitals and Clinics cater to a wide range of diagnostic equipment and services such as imaging studies, pulmonary function tests, and molecular diagnostics; hence it offers a complete solution for respiratory health assessment. As a result, the segment positioning in this whole input-output course of illness diagnosis, management, and therapy clearly puts hospitals and clinics within this input-output chain addressing the emerging demand for respiratory diagnostics in many healthcare institutions. “North America to witness the fastest CAGR in the respiratory diagnostics market during the forecast period.” Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America is expected to be in the leading position, holding the largest share of the global respiratory diagnostic market. This leadership position had been fueled by a highly developed healthcare system, along with high prevalence rates of respiratory diseases and considerable expenditure toward innovation in healthcare. According to their advanced diagnostic technologies, the focus is toward accurate and rapid testing; hence, they tend to give all of the parameters, including increased healthcare spending, larger aging populations, and strong emphasis on public health initiatives that are caused by respiratory issues, for example. Their overall regulatory framework encourages the adoption of these diagnostic solutions for continued growth. Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25% • By Designation: C-level – 30%, Director-level – 23%, and Others – 47% • By Region: North America - 25%, Europe – 35%, APAC – 20%, Latin America – 13%, Middle East & Africa – 7% Breakdown of demand-side primary interviews: • By Company Type: Hospitals & Clinics – 62%, Diagnostics Laboratories – 16%, and Other End Users – 22% • By Designation: Senior Managers – 35%, Chief Officers – 28%, Radiologists – 25% and Other Designations – 12% • By Region: North America - 32%, Europe – 25%, APAC – 20%, Latin America – 14%, Middle East & Africa – 9% Research Coverage This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries. Reasons to Buy the Report The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies. This report provides insights into the following pointers: • Analysis of key drivers (increasing incidences of respiratory disorders, growing aging population and changing lifestyle, growing awareness about respiratory health, advancements in diagnostic technologies), restraints (high cost of diagnostic tests, limited reimbursement coverage, and lack of skilled professionals for advanced diagnostics), opportunities (increasing healthcare infrastructure and rising disposable incomes in emerging economies, rising demand for Point-of-care (POC) testing, and growing awareness of untreated sleep apnea), and challenges (complexity in diagnosing viral respiratory infections, and limited access to peripheral lung lesions in bronchoscopy) influencing the growth of respiratory diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market. • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions. • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market. • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.
目錄 Table of Contents
1 INTRODUCTION 33 1.1 STUDY OBJECTIVES 33 1.2 MARKET DEFINITION 33 1.3 MARKET SCOPE 34 1.3.1 MARKETS & REGIONS COVERED 34 1.3.2 INCLUSIONS & EXCLUSIONS 35 1.3.3 YEARS CONSIDERED 35 1.3.4 CURRENCY CONSIDERED 36 1.4 STAKEHOLDERS 36 1.5 SUMMARY OF CHANGES 36 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 38 2.1.1.1 Key data from secondary sources 39 2.1.2 PRIMARY DATA 40 2.1.2.1 Primary research objectives 40 2.1.2.2 Key data from primary sources 41 2.1.2.3 Key industry insights 42 2.1.2.4 Breakdown of primary interviews 42 2.2 MARKET SIZE ESTIMATION 44 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 44 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 45 2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS 46 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 49 2.4 MARKET SHARE ESTIMATION 50 2.5 STUDY ASSUMPTIONS 50 2.6 RESEARCH LIMITATIONS 51 2.6.1 METHODOLOGY-RELATED LIMITATIONS 51 2.6.2 SCOPE-RELATED LIMITATIONS 51 2.7 RISK ASSESSMENT 51 3 EXECUTIVE SUMMARY 52 4 PREMIUM INSIGHTS 56 4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW 56 4.2 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023) 57   4.3 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX 58 4.4 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58 5 MARKET OVERVIEW 59 5.1 INTRODUCTION 59 5.2 MARKET DYNAMICS 59 5.2.1 DRIVERS 60 5.2.1.1 Increasing incidence of respiratory disorders 60 5.2.1.2 Expanding geriatric population and rise in sedentary lifestyles 61 5.2.1.3 Growing awareness about respiratory health 61 5.2.1.4 Advancements in diagnostic technologies 62 5.2.2 RESTRAINTS 62 5.2.2.1 High cost of diagnostic tests 62 5.2.2.2 Limited reimbursements 63 5.2.2.3 Shortage of skilled professionals 63 5.2.3 OPPORTUNITIES 63 5.2.3.1 High growth potential of emerging economies 63 5.2.3.2 Increasing demand for POC testing 64 5.2.3.3 Growing awareness about untreated OSA 64 5.2.4 CHALLENGES 66 5.2.4.1 Complexities associated with diagnosis of viral respiratory infections 66 5.2.4.2 Limited access to peripheral lung lesions in bronchoscopy 66 5.3 INDUSTRY TRENDS 67 5.3.1 POINT-OF-CARE TESTING 67 5.3.2 PERSONALIZED MEDICINE 67 5.4 TECHNOLOGY ANALYSIS 68 5.4.1 KEY TECHNOLOGIES 68 5.4.1.1 Home-based & personal DHTs 68 5.4.1.2 PFT tools and molecular & imaging diagnostics 68 5.4.2 COMPLEMENTARY TECHNOLOGIES 69 5.4.2.1 AI-enhanced imaging 69 5.4.2.2 Serological & telehealth platforms 69 5.4.3 ADJACENT TECHNOLOGIES 69 5.4.3.1 Rapid respiratory diagnostic tests 69 5.5 PORTER’S FIVE FORCES ANALYSIS 70 5.5.1 THREAT OF NEW ENTRANTS 71 5.5.2 THREAT OF SUBSTITUTES 71 5.5.3 BARGAINING POWER OF SUPPLIERS 71 5.5.4 BARGAINING POWER OF BUYERS 71 5.5.5 INTENSITY OF COMPETITIVE RIVALRY 71   5.6 REGULATORY ANALYSIS 72 5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.6.2 REGULATORY LANDSCAPE 75 5.6.2.1 North America 75 5.6.2.1.1 US 75 5.6.2.1.2 Canada 76 5.6.2.2 Europe 77 5.6.2.3 Asia Pacific 77 5.6.2.3.1 India 77 5.6.2.3.2 China 77 5.6.2.3.3 Japan 78 5.6.2.4 Latin America 79 5.6.2.5 Middle East & Africa 79 5.7 PATENT ANALYSIS 79 5.7.1 KEY PATENTS GRANTED 81 5.8 TRADE ANALYSIS 82 5.8.1 IMPORT DATA FOR HS CODE 901819 82 5.8.2 EXPORT DATA FOR HS CODE 901819 83 5.9 PRICING ANALYSIS 83 5.9.1 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY KEY PLAYER (2024) 84 5.9.2 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023 85 5.10 VALUE CHAIN ANALYSIS 86 5.11 KEY STAKEHOLDERS & BUYING CRITERIA 87 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 87 5.11.2 KEY BUYING CRITERIA 88 5.12 KEY CONFERENCES & EVENTS, 2024–2025 89 5.13 UNMET NEEDS/END-USER EXPECTATIONS 89 5.14 ADJACENT MARKET ANALYSIS 90 5.15 ECOSYSTEM ANALYSIS 91 5.16 CASE STUDY ANALYSIS 93 5.17 SUPPLY CHAIN ANALYSIS 94 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96 5.19 INVESTMENT & FUNDING SCENARIO 97 5.20 REIMBURSEMENT SCENARIO 97 5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET 99 6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 100 6.1 INTRODUCTION 101 6.2 INSTRUMENTS & DEVICES 101 6.2.1 INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS TO DRIVE MARKET 101 6.3 ASSAYS & REAGENTS 103 6.3.1 INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET 103 6.4 SERVICES & SOFTWARE 104 6.4.1 INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET 104 7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE 106 7.1 INTRODUCTION 107 7.2 MECHANICAL TESTS 107 7.2.1 PULMONARY FUNCTION TESTS 109 7.2.1.1 Spirometry 111 7.2.1.1.1 Diagnosis of COPD and pulmonary fibrosis to drive market 111 7.2.1.2 Peak flow tests 113 7.2.1.2.1 Ability to provide accurate lung function monitoring with non-invasiveness benefits to fuel uptake 113 7.2.1.3 Other pulmonary function tests 115 7.2.2 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS 117 7.2.2.1 Large presence of untreated population to drive market 117 7.2.3 OTHER MECHANICAL TESTS 118 7.3 IMAGING TESTS 120 7.3.1 X-RAY 121 7.3.1.1 Integration of AI into X-ray devices for enhanced imaging capabilities to drive market 121 7.3.2 COMPUTED TOMOGRAPHY 122 7.3.2.1 Rising focus on obtaining high-resolution CT images to boost demand 122 7.3.3 MAGNETIC RESONANCE IMAGING (MRI) 123 7.3.3.1 Ability to provide detailed lung images without radiation exposure to drive market 123 7.3.4 POSITRON EMISSION TOMOGRAPHY (PET) 125 7.3.4.1 Growing focus on detection & monitoring of treatment response to lung cancer to drive market 125 7.3.5 OTHER IMAGING TESTS 126 7.4 TRADITIONAL DIAGNOSTIC TESTS 127 7.4.1 IMMUNODIAGNOSTICS 128 7.4.1.1 Rising demand for rapid disease diagnosis to fuel uptake 128 7.4.2 BIOCHEMICAL TESTS 129 7.4.2.1 Ability to accurately measure biomarkers in pneumonia and bronchitis infections to boost demand 129 7.4.3 MICROSCOPY 131 7.4.3.1 Inadequate sensitivity towards emerging viruses to restrain market 131 7.5 MOLECULAR DIAGNOSTIC TESTS 132 7.5.1 POLYMERASE CHAIN REACTION (PCR) 133 7.5.1.1 Development of portable and real-time PCR machines to drive market 133 7.5.2 NUCLEIC ACID AMPLIFICATION TEST (NAAT) 134 7.5.2.1 Rapid identification of viral, bacterial, and fungal infections to fuel demand 134 7.5.3 IN SITU HYBRIDIZATION (ISH) 136 7.5.3.1 Utilization of probes for pathogen detection to support market growth 136 7.5.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 137 7.5.4.1 High-throughput capabilities for rapid analysis of genetic data to propel market 137 7.5.5 MICROARRAYS 138 7.5.5.1 Detection of hepatitis C and respiratory viruses to support market growth 138 7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS 140 8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 141 8.1 INTRODUCTION 142 8.2 TUBERCULOSIS 142 8.2.1 FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET 142 8.3 ASTHMA 143 8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET 143 8.4 LUNG CANCER 145 8.4.1 NON-SMALL-CELL LUNG CANCER (NSCLC) 146 8.4.1.1 Rising investments in advanced radiographic technologies to fuel market 146 8.4.2 SMALL-CELL LUNG CANCER (SCLC) 147 8.4.2.1 Growing emphasis on precision testing to drive market 147 8.4.3 OTHER LUNG CANCERS 148 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 149 8.5.1 ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR COPD DIAGNOSIS TO FUEL MARKET 149 8.6 PNEUMONIA 151 8.6.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND 151 8.7 OTHER DISEASES 153 9 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 154 9.1 INTRODUCTION 155 9.2 SYNDROMIC DIAGNOSIS 155 9.2.1 DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET 155 9.3 ETIOLOGICAL DIAGNOSIS 156 9.3.1 IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET 156 9.4 PROGNOSIS DIAGNOSIS 158 9.4.1 ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH 158   10 RESPIRATORY DIAGNOSTICS MARKET, BY END USER 160 10.1 INTRODUCTION 161 10.2 HOSPITALS & CLINICS 161 10.2.1 GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET 161 10.3 DIAGNOSTIC LABORATORIES 163 10.3.1 ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS TO BOOST DEMAND 163 10.4 LONG-TERM CARE & SPECIALTY CENTERS 164 10.4.1 PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET 164 10.5 ACADEMIC & RESEARCH INSTITUTES 165 10.5.1 FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH 165 11 RESPIRATORY DIAGNOSTICS MARKET, BY REGION 166 11.1 INTRODUCTION 167 11.2 NORTH AMERICA 168 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 168 11.2.2 US 174 11.2.2.1 Growing accessibility to technologically advanced products to boost demand 174 11.2.3 CANADA 178 11.2.3.1 Rising incidence of COPD to drive market 178 11.3 EUROPE 183 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 183 11.3.2 GERMANY 188 11.3.2.1 Increasing public healthcare expenditure to foster market growth 188 11.3.3 UK 192 11.3.3.1 Rising establishment of hospitals and increasing number of surgical procedures to fuel market 192 11.3.4 FRANCE 197 11.3.4.1 High prevalence of smoking and increasing demand for respiratory devices to drive market 197 11.3.5 ITALY 201 11.3.5.1 Unfavorable amendments to healthcare policies to restrain market 201 11.3.6 SPAIN 206 11.3.6.1 Increasing demand for home healthcare services to support market growth 206 11.3.7 REST OF EUROPE 210 11.4 ASIA PACIFIC 215 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 215 11.4.2 JAPAN 221 11.4.2.1 Availability of universal healthcare reimbursement policy to drive market 221 11.4.3 CHINA 225 11.4.3.1 High incidence of viral respiratory infections to propel market 225   11.4.4 INDIA 230 11.4.4.1 Expansion of leading medical device manufacturers and large target patient population to drive market 230 11.4.5 AUSTRALIA 234 11.4.5.1 High prevalence of chronic lung diseases to boost demand 234 11.4.6 SOUTH KOREA 238 11.4.6.1 Expanding geriatric population and rising incidence of chronic respiratory conditions to fuel market 238 11.4.7 REST OF ASIA PACIFIC 243 11.5 LATIN AMERICA 247 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 247 11.5.2 BRAZIL 251 11.5.2.1 Favorable government initiatives for healthcare sector improvement to drive market 251 11.5.3 MEXICO 256 11.5.3.1 Rising prevalence of obesity & hypertension to fuel uptake 256 11.5.4 REST OF LATIN AMERICA 260 11.6 MIDDLE EAST & AFRICA 264 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 264 11.6.2 GCC COUNTRIES 269 11.6.2.1 Kingdom of Saudi Arabia (KSA) 273 11.6.2.1.1 Investments in advanced healthcare technologies to drive market 273 11.6.2.2 United Arab Emirates (UAE) 277 11.6.2.2.1 Rising prevalence of asthma to support market growth 277 11.6.2.3 Other GCC Countries 282 11.6.3 REST OF MIDDLE EAST & AFRICA 286 12 COMPETITIVE LANDSCAPE 290 12.1 INTRODUCTION 290 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021–DECEMBER 2024 290 12.3 REVENUE ANALYSIS, 2019–2023 291 12.4 MARKET SHARE ANALYSIS, 2023 292 12.4.1 RANKING OF KEY MARKET PLAYERS 294 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 295 12.5.1 STARS 295 12.5.2 EMERGING LEADERS 295 12.5.3 PERVASIVE PLAYERS 295 12.5.4 PARTICIPANTS 295 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 297 12.5.5.1 Company footprint 297 12.5.5.2 Region footprint 298 12.5.5.3 Product & service footprint 299 12.5.5.4 Test type footprint 300 12.5.5.5 Disease type footprint 301 12.5.5.6 End-user footprint 302 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 303 12.6.1 PROGRESSIVE COMPANIES 303 12.6.2 RESPONSIVE COMPANIES 303 12.6.3 DYNAMIC COMPANIES 303 12.6.4 STARTING BLOCKS 303 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 305 12.7 BRAND/PRODUCT COMPARISON 307 12.8 R&D EXPENDITURE OF KEY PLAYERS 308 12.9 COMPANY VALUATION & FINANCIAL METRICS 308 12.9.1 FINANCIAL METRICS 308 12.9.2 COMPANY VALUATION 309 12.10 COMPETITIVE SCENARIO 309 12.10.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 309 12.10.2 DEALS 310 12.10.3 EXPANSIONS 311 12.10.4 OTHER DEVELOPMENTS 312 13 COMPANY PROFILES 313 13.1 KEY PLAYERS 313 13.1.1 KONINKLIJKE PHILIPS N.V. 313 13.1.1.1 Business overview 313 13.1.1.2 Products & services offered 314 13.1.1.3 Recent developments 316 13.1.1.3.1 Product launches 316 13.1.1.3.2 Deals 316 13.1.1.3.3 Expansions 317 13.1.1.4 MnM view 317 13.1.1.4.1 Key strengths 317 13.1.1.4.2 Strategic choices 318 13.1.1.4.3 Weaknesses & competitive threats 318 13.1.2 BECTON, DICKINSON AND COMPANY 319 13.1.2.1 Business overview 319 13.1.2.2 Products & services offered 321 13.1.2.3 Recent developments 322 13.1.2.3.1 Product launches & approvals 322 13.1.2.3.2 Deals 323 13.1.2.4 MnM view 324 13.1.2.4.1 Key strengths 324 13.1.2.4.2 Strategic choices 324 13.1.2.4.3 Weaknesses & competitive threats 324 13.1.3 ABBOTT LABORATORIES 325 13.1.3.1 Business overview 325 13.1.3.2 Products & services offered 326 13.1.3.3 Recent developments 327 13.1.3.3.1 Product approvals 327 13.1.3.4 MnM view 327 13.1.3.4.1 Key strengths 327 13.1.3.4.2 Strategic choices 327 13.1.3.4.3 Weaknesses & competitive threats 327 13.1.4 THERMO FISHER SCIENTIFIC INC. 328 13.1.4.1 Business overview 328 13.1.4.2 Products & services offered 329 13.1.4.3 Recent developments 331 13.1.4.3.1 Product & service launches 331 13.1.4.3.2 Deals 332 13.1.4.4 MnM view 332 13.1.4.4.1 Key strengths 332 13.1.4.4.2 Strategic choices 332 13.1.4.4.3 Weaknesses & competitive threats 332 13.1.5 GE HEALTHCARE TECHNOLOGIES, INC. 333 13.1.5.1 Business overview 333 13.1.5.2 Products & services offered 334 13.1.5.3 Recent developments 337 13.1.5.3.1 Product & service launches & approvals 337 13.1.5.3.2 Deals 338 13.1.5.3.3 Other developments 339 13.1.5.4 MnM view 340 13.1.5.4.1 Key strengths 340 13.1.5.4.2 Strategic choices 340 13.1.5.4.3 Weaknesses & competitive threats 340 13.1.6 BIO-RAD LABORATORIES, INC. 341 13.1.6.1 Business overview 341 13.1.6.2 Products & services offered 342 13.1.6.3 Recent developments 344 13.1.6.3.1 Product launches & approvals 344 13.1.6.3.2 Deals 345 13.1.7 BIOMÉRIEUX 346 13.1.7.1 Business overview 346 13.1.7.2 Products & services offered 347 13.1.7.3 Recent developments 348 13.1.7.3.1 Product launches & approvals 348 13.1.7.3.2 Deals 348 13.1.8 REVVITY, INC. 349 13.1.8.1 Business overview 349 13.1.8.2 Products & services offered 350 13.1.8.3 Recent developments 352 13.1.8.3.1 Product launches & approvals 352 13.1.8.3.2 Deals 352 13.1.9 SEEGENE INC. 353 13.1.9.1 Business overview 353 13.1.9.2 Products & services offered 354 13.1.9.3 Recent developments 356 13.1.9.3.1 Product launches & approvals 356 13.1.9.3.2 Deals 356 13.1.9.3.3 Expansions 357 13.1.9.3.4 Other developments 357 13.1.10 NIHON KOHDEN CORPORATION 358 13.1.10.1 Business overview 358 13.1.10.2 Products & services offered 360 13.1.11 VITALOGRAPH 361 13.1.11.1 Business overview 361 13.1.11.2 Products & services offered 361 13.1.11.3 Recent developments 362 13.1.11.3.1 Product & service launches & approvals 362 13.1.11.3.2 Deals 363 13.1.12 SDI DIAGNOSTICS 364 13.1.12.1 Business overview 364 13.1.12.2 Products & services offered 365 13.1.13 RESMED INC. 366 13.1.13.1 Business overview 366 13.1.13.2 Products & services offered 367 13.1.13.3 Recent developments 368 13.1.13.3.1 Deals 368 13.1.13.3.2 Expansions 368 13.1.13.3.3 Other developments 368 13.1.14 SIEMENS HEALTHINEERS AG 369 13.1.14.1 Business overview 369 13.1.14.2 Products & services offered 370 13.1.14.3 Recent developments 372 13.1.14.3.1 Product launches 372 13.1.14.3.2 Deals 372 13.1.14.3.3 Expansions 373   13.1.15 COSMED SRL 374 13.1.15.1 Business overview 374 13.1.15.2 Products & services offered 374 13.1.15.3 Recent developments 375 13.1.15.3.1 Product launches 375 13.1.15.3.2 Deals 375 13.1.16 HOLOGIC, INC. 376 13.1.16.1 Business overview 376 13.1.16.2 Products & services offered 378 13.1.16.3 Recent developments 379 13.1.16.3.1 Product launches 379 13.1.16.3.2 Deals 379 13.1.17 QIAGEN N.V. 380 13.1.17.1 Business overview 380 13.1.17.2 Products & services offered 381 13.1.17.3 Recent developments 383 13.1.17.3.1 Product launches 383 13.1.17.3.2 Deals 384 13.1.17.3.3 Other developments 384 13.2 OTHER PLAYERS 385 13.2.1 MGC DIAGNOSTICS CORPORATION 385 13.2.2 VISBY MEDICAL, INC. 386 13.2.3 BRIOTA TECHNOLOGIES PVT. LTD. 386 13.2.4 BIRD HEALTHCARE 387 13.2.5 LÖWENSTEIN MEDICAL SE & CO. KG 388 13.2.6 PROAXSIS 388 13.2.7 NDD MEDICAL TECHNOLOGIES 389 13.2.8 COMPUMEDICS LIMITED 390 14 APPENDIX 391 14.1 DISCUSSION GUIDE 391 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 400 14.3 CUSTOMIZATION OPTIONS 402 14.4 RELATED REPORTS 402 14.5 AUTHOR DETAILS 403
圖表清單 List of Tables & Figures
TABLE 1 RESPIRATORY DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 35 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 36 TABLE 3 RESPIRATORY DIAGNOSTICS MARKET: STUDY ASSUMPTIONS 50 TABLE 4 RESPIRATORY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 51 TABLE 5 AWARENESS INITIATIVES ON EFFECTS OF UNTREATED SLEEP APNEA 65 TABLE 6 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70 TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 12 US: CLASSIFICATION OF MEDICAL EQUIPMENT 75 TABLE 13 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 76 TABLE 14 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 76 TABLE 15 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77 TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78 TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78 TABLE 18 RESPIRATORY DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024 81 TABLE 19 IMPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND) 82 TABLE 20 EXPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND) 83 TABLE 21 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023 (USD) 85 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES 87 TABLE 23 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 88 TABLE 24 RESPIRATORY DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2024−2025 89 TABLE 25 RESPIRATORY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 92 TABLE 26 CASE STUDY 1: ACUPEBBLE SA100 – TRANSFORMING SLEEP APNEA DIAGNOSIS 93 TABLE 27 CASE STUDY 2: REMOTE MONITORING SOLUTION FOR COVID-19 PATIENTS IN INDONESIA 93 TABLE 28 CASE STUDY 3: EFFECTIVE MANAGEMENT OF A 71-YEAR-OLD COPD PATIENT WITH ACUTE EXACERBATIONS 94 TABLE 29 RESPIRATORY DIAGNOSTICS MARKET: REIMBURSEMENT SCENARIO 97 TABLE 30 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 101 TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS & DEVICES, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 32 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 33 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 34 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 107 TABLE 35 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 108 TABLE 36 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2022–2030 (USD MILLION) 109 TABLE 37 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 110 TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY TYPE, 2022–2030 (USD MILLION) 111 TABLE 39 SPIROMETRY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 112 TABLE 40 SPIROMETRY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 113 TABLE 41 PEAK FLOW TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 114 TABLE 42 PEAK FLOW TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 115 TABLE 43 OTHER PULMONARY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 44 OTHER PULMONARY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 117 TABLE 45 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 46 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 119 TABLE 47 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 120 TABLE 48 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2022–2030 (USD MILLION) 121 TABLE 49 X-RAY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 50 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 51 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 52 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 125 TABLE 53 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 126 TABLE 54 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 55 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION) 128 TABLE 56 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 129 TABLE 57 BIOCHEMICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 58 MICROSCOPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131 TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION) 133 TABLE 61 PCR MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 134 TABLE 62 NUCLEIC ACID AMPLIFICATION TEST MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 63 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 64 DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 65 MICROARRAYS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 139 TABLE 66 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 67 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 142 TABLE 68 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2030 (USD MILLION) 143 TABLE 69 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 70 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 71 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 72 NON-SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 147 TABLE 73 SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 148 TABLE 74 OTHER LUNG CANCERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 149 TABLE 75 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 76 RESPIRATORY DIAGNOSTICS MARKET FOR PNEUMONIA, BY COUNTRY, 2022–2030 (USD MILLION) 152 TABLE 77 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 153 TABLE 78 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 155 TABLE 79 SYNDROMIC DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 156 TABLE 80 ETIOLOGICAL DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157 TABLE 81 PROGNOSIS DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159 TABLE 82 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 161 TABLE 83 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 162 TABLE 84 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 163 TABLE 85 RESPIRATORY DIAGNOSTICS MARKET FOR LONG-TERM CARE & SPECIALTY CENTERS, BY COUNTRY, 2022–2030 (USD MILLION) 164 TABLE 86 RESPIRATORY DIAGNOSTICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION) 165 TABLE 87 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 168 TABLE 88 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 170 TABLE 89 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 170 TABLE 90 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 170 TABLE 91 NORTH AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171 TABLE 92 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171 TABLE 93 NORTH AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171 TABLE 94 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 96 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 172 TABLE 97 NORTH AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 173 TABLE 98 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 173 TABLE 99 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 173 TABLE 100 US: KEY MACROINDICATORS 174 TABLE 101 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 175 TABLE 102 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 175 TABLE 103 US: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 175 TABLE 104 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 105 US: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 106 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 107 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 177 TABLE 108 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 177 TABLE 109 US: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 177 TABLE 110 US: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 178 TABLE 111 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 178 TABLE 112 CANADA: KEY MACROINDICATORS 179 TABLE 113 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 179 TABLE 114 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 179 TABLE 115 CANADA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 116 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 117 CANADA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 118 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 119 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 181 TABLE 120 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 181 TABLE 121 CANADA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 182 TABLE 122 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 182 TABLE 123 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 182 TABLE 124 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 184 TABLE 125 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 184 TABLE 126 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 184 TABLE 127 EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 128 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 129 EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 130 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 186 TABLE 131 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 186 TABLE 132 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 186 TABLE 133 EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 187 TABLE 134 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 187 TABLE 135 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 187 TABLE 136 GERMANY: KEY MACROINDICATORS 188 TABLE 137 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 188 TABLE 138 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 189 TABLE 139 GERMANY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 140 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 141 GERMANY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 142 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 143 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 144 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 191 TABLE 145 GERMANY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 191 TABLE 146 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 191 TABLE 147 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 192 TABLE 148 UK: KEY MACROINDICATORS 193 TABLE 149 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 193 TABLE 150 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 193 TABLE 151 UK: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194 TABLE 152 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194 TABLE 153 UK: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194 TABLE 154 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 155 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 156 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 195 TABLE 157 UK: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 158 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 196 TABLE 159 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 196 TABLE 160 FRANCE: KEY MACROINDICATORS 197 TABLE 161 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 197 TABLE 162 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 198 TABLE 163 FRANCE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 164 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 165 FRANCE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 166 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 167 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 168 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 200 TABLE 169 FRANCE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 200 TABLE 170 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 200 TABLE 171 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 201 TABLE 172 ITALY: KEY MACROINDICATORS 202 TABLE 173 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 202 TABLE 174 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 202 TABLE 175 ITALY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203 TABLE 176 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203 TABLE 177 ITALY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203 TABLE 178 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 179 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 180 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 204 TABLE 181 ITALY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 205 TABLE 182 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 205 TABLE 183 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 205 TABLE 184 SPAIN: KEY MACROINDICATORS 206 TABLE 185 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 207 TABLE 186 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 207 TABLE 187 SPAIN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 207 TABLE 188 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 189 SPAIN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 190 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 191 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 209 TABLE 192 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 209 TABLE 193 SPAIN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 209 TABLE 194 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 210 TABLE 195 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 210 TABLE 196 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 211 TABLE 197 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 211 TABLE 198 REST OF EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 211 TABLE 199 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 200 REST OF EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 201 REST OF EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 202 REST OF EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 213 TABLE 203 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 213 TABLE 204 REST OF EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 213 TABLE 205 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 214 TABLE 206 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 214 TABLE 207 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 217 TABLE 208 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 217 TABLE 209 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 217 TABLE 210 ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 218 TABLE 211 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 218 TABLE 212 ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 218 TABLE 213 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 219 TABLE 214 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 219 TABLE 215 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 219 TABLE 216 ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 220 TABLE 217 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 220 TABLE 218 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 220 TABLE 219 JAPAN: KEY MACROINDICATORS 221 TABLE 220 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 221 TABLE 221 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 222 TABLE 222 JAPAN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 222 TABLE 223 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 222 TABLE 224 JAPAN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223 TABLE 225 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223 TABLE 226 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223 TABLE 227 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 224 TABLE 228 JAPAN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 224 TABLE 229 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 224 TABLE 230 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 225 TABLE 231 CHINA: KEY MACROINDICATORS 226 TABLE 232 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 226 TABLE 233 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 226 TABLE 234 CHINA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 235 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 236 CHINA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 237 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 228 TABLE 238 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 228 TABLE 239 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 228 TABLE 240 CHINA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 229 TABLE 241 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 229 TABLE 242 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 229 TABLE 243 INDIA: KEY MACROINDICATORS 230 TABLE 244 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 230 TABLE 245 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 231 TABLE 246 INDIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 247 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 248 INDIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232 TABLE 249 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232 TABLE 250 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232 TABLE 251 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 233 TABLE 252 INDIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 233 TABLE 253 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 233 TABLE 254 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 234 TABLE 255 AUSTRALIA: KEY MACROINDICATORS 234 TABLE 256 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 235 TABLE 257 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 235 TABLE 258 AUSTRALIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 235 TABLE 259 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 260 AUSTRALIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 261 AUSTRALIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 262 AUSTRALIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 237 TABLE 263 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 237 TABLE 264 AUSTRALIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 237 TABLE 265 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 238 TABLE 266 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 238 TABLE 267 SOUTH KOREA: KEY MACROINDICATORS 239 TABLE 268 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 239 TABLE 269 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 239 TABLE 270 SOUTH KOREA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 240 TABLE 271 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 240 TABLE 272 SOUTH KOREA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 240 TABLE 273 SOUTH KOREA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 241 TABLE 274 SOUTH KOREA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 241 TABLE 275 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 241 TABLE 276 SOUTH KOREA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 242 TABLE 277 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 242 TABLE 278 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 242 TABLE 279 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 243 TABLE 280 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 243 TABLE 281 REST OF ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 282 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 283 REST OF ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 284 REST OF ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 245 TABLE 285 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 245 TABLE 286 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 245 TABLE 287 REST OF ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 246 TABLE 288 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 246 TABLE 289 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 246 TABLE 290 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 247 TABLE 291 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 248 TABLE 292 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 248 TABLE 293 LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 248 TABLE 294 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 249 TABLE 295 LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 249 TABLE 296 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 249 TABLE 297 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 250 TABLE 298 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 250 TABLE 299 LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 250 TABLE 300 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 251 TABLE 301 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 251 TABLE 302 BRAZIL: KEY MACROINDICATORS 252 TABLE 303 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 252 TABLE 304 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 252 TABLE 305 BRAZIL: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 253 TABLE 306 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 253 TABLE 307 BRAZIL: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 253 TABLE 308 BRAZIL: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 254 TABLE 309 BRAZIL: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 254 TABLE 310 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 254 TABLE 311 BRAZIL: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 255 TABLE 312 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 255 TABLE 313 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 255 TABLE 314 MEXICO: KEY MACROINDICATORS 256 TABLE 315 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 256 TABLE 316 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 257 TABLE 317 MEXICO: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 257 TABLE 318 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 257 TABLE 319 MEXICO: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 258 TABLE 320 MEXICO: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 258 TABLE 321 MEXICO: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 258 TABLE 322 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 259 TABLE 323 MEXICO: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 259 TABLE 324 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 259 TABLE 325 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 260 TABLE 326 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 260 TABLE 327 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 261 TABLE 328 REST OF LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 261 TABLE 329 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 261 TABLE 330 REST OF LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 262 TABLE 331 REST OF LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 262 TABLE 332 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 262 TABLE 333 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 263 TABLE 334 REST OF LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 263 TABLE 335 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 263 TABLE 336 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 264 TABLE 337 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 265 TABLE 338 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 265 TABLE 339 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 265 TABLE 340 MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 266 TABLE 341 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 266 TABLE 342 MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 266 TABLE 343 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 267 TABLE 344 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 267 TABLE 345 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 267 TABLE 346 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 268 TABLE 347 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 268 TABLE 348 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 268 TABLE 349 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 269 TABLE 350 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 269 TABLE 351 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 270 TABLE 352 GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 270 TABLE 353 GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 270 TABLE 354 GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 271 TABLE 355 GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 271 TABLE 356 GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 271 TABLE 357 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 272 TABLE 358 GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 272 TABLE 359 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 272 TABLE 360 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 273 TABLE 361 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 273 TABLE 362 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 274 TABLE 363 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 274 TABLE 364 KINGDOM OF SAUDI ARABIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 274 TABLE 365 KINGDOM OF SAUDI ARABIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 275 TABLE 366 KINGDOM OF SAUDI ARABIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 275 TABLE 367 KINGDOM OF SAUDI ARABIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 275 TABLE 368 KINGDOM OF SAUDI ARABIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 276 TABLE 369 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 276 TABLE 370 KINGDOM OF SAUDI ARABIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 276 TABLE 371 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 277 TABLE 372 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 277 TABLE 373 UNITED ARAB EMIRATES: KEY MACROINDICATORS 278 TABLE 374 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 278 TABLE 375 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 278 TABLE 376 UNITED ARAB EMIRATES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 279 TABLE 377 UNITED ARAB EMIRATES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 279 TABLE 378 UNITED ARAB EMIRATES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 279 TABLE 379 UNITED ARAB EMIRATES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 280 TABLE 380 UNITED ARAB EMIRATES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 280 TABLE 381 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 280 TABLE 382 UNITED ARAB EMIRATES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 281 TABLE 383 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 281 TABLE 384 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 281 TABLE 385 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 282 TABLE 386 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 282 TABLE 387 OTHER GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 283 TABLE 388 OTHER GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 283 TABLE 389 OTHER GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 283 TABLE 390 OTHER GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 284 TABLE 391 OTHER GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 284 TABLE 392 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 284 TABLE 393 OTHER GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 285 TABLE 394 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 285 TABLE 395 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 285 TABLE 396 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 286 TABLE 397 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 286 TABLE 398 REST OF MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 287 TABLE 399 REST OF MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 287 TABLE 400 REST OF MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 287 TABLE 401 REST OF MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 288 TABLE 402 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 288 TABLE 403 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 288 TABLE 404 REST OF MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 289 TABLE 405 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 289 TABLE 406 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 289 TABLE 407 RESPIRATORY DIAGNOSTIC MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021–DECEMBER 2024 290 TABLE 408 RESPIRATORY DIAGNOSTICS MARKET: DEGREE OF COMPETITION, 2023 293 TABLE 409 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL FOOTPRINT 298 TABLE 410 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 299 TABLE 411 RESPIRATORY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT 300 TABLE 412 RESPIRATORY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT 301 TABLE 413 RESPIRATORY DIAGNOSTICS MARKET: END-USER FOOTPRINT 302 TABLE 414 RESPIRATORY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 305 TABLE 415 RESPIRATORY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 306 TABLE 416 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 309 TABLE 417 RESPIRATORY DIAGNOSTICS MARKET: DEALS, JANUARY 2021–DECEMBER 2024 310 TABLE 418 RESPIRATORY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024 311 TABLE 419 RESPIRATORY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 312 TABLE 420 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 313 TABLE 421 KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED 314 TABLE 422 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 316 TABLE 423 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–DECEMBER 2024 316 TABLE 424 KONINKLIJKE PHILIPS N.V.: EXPANSIONS, JANUARY 2021–DECEMBER 2024 317 TABLE 425 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 319 TABLE 426 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 321 TABLE 427 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 322 TABLE 428 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–DECEMBER 2024 323 TABLE 429 ABBOTT LABORATORIES: COMPANY OVERVIEW 325 TABLE 430 ABBOTT LABORATORIES: PRODUCTS & SERVICES OFFERED 326 TABLE 431 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021–DECEMBER 2024 327 TABLE 432 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 328 TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 329 TABLE 434 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2021–DECEMBER 2024 331 TABLE 435 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–DECEMBER 2024 332 TABLE 436 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY OVERVIEW 333 TABLE 437 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 334 TABLE 438 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 337 TABLE 439 GE HEALTHCARE TECHNOLOGIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024 338 TABLE 440 GE HEALTHCARE TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024 339 TABLE 441 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 341 TABLE 442 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 342 TABLE 443 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 344 TABLE 444 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024 345 TABLE 445 BIOMÉRIEUX: COMPANY OVERVIEW 346 TABLE 446 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 347 TABLE 447 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 348 TABLE 448 BIOMÉRIEUX: DEALS, JANUARY 2021–DECEMBER 2024 348 TABLE 449 REVVITY, INC.: COMPANY OVERVIEW 349 TABLE 450 REVVITY, INC.: PRODUCTS & SERVICES OFFERED 350 TABLE 451 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 352 TABLE 452 REVVITY, INC.: DEALS, JANUARY 2021–DECEMBER 2024 352 TABLE 453 SEEGENE INC.: COMPANY OVERVIEW 353 TABLE 454 SEEGENE INC.: PRODUCTS & SERVICES OFFERED 354 TABLE 455 SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 356 TABLE 456 SEEGENE INC.: DEALS, JANUARY 2021–DECEMBER 2024 356 TABLE 457 SEEGENE INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024 357 TABLE 458 SEEGENE INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024 357 TABLE 459 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 358 TABLE 460 NIHON KOHDEN CORPORATION: PRODUCTS & SERVICES OFFERED 360 TABLE 461 VITALOGRAPH: COMPANY OVERVIEW 361 TABLE 462 VITALOGRAPH: PRODUCTS & SERVICES OFFERED 361 TABLE 463 VITALOGRAPH: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024 362 TABLE 464 VITALOGRAPH: DEALS, JANUARY 2021–DECEMBER 2024 363 TABLE 465 SDI DIAGNOSTICS: COMPANY OVERVIEW 364 TABLE 466 SDI DIAGNOSTICS: PRODUCTS & SERVICES OFFERED 365 TABLE 467 RESMED INC.: COMPANY OVERVIEW 366 TABLE 468 RESMED INC.: PRODUCTS & SERVICES OFFERED 367 TABLE 469 RESMED INC.: DEALS, JANUARY 2021–DECEMBER 2024 368 TABLE 470 RESMED INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024 368 TABLE 471 RESMED INC.: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 368 TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 369 TABLE 473 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED 370 TABLE 474 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 372 TABLE 475 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–DECEMBER 2024 372 TABLE 476 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024 373 TABLE 477 COSMED SRL: COMPANY OVERVIEW 374 TABLE 478 COSMED SRL: PRODUCTS & SERVICES OFFERED 374 TABLE 479 COSMED SRL: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 375 TABLE 480 COSMED SRL: DEALS, JANUARY 2021–DECEMBER 2024 375 TABLE 481 HOLOGIC, INC.: COMPANY OVERVIEW 376 TABLE 482 HOLOGIC, INC.: PRODUCTS & SERVICES OFFERED 378 TABLE 483 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 379 TABLE 484 HOLOGIC, INC.: DEALS, JANUARY 2021–DECEMBER 2024 379 TABLE 485 QIAGEN N.V.: COMPANY OVERVIEW 380 TABLE 486 QIAGEN N.V.: PRODUCTS & SERVICES OFFERED 381 TABLE 487 QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 383 TABLE 488 QIAGEN N.V.: DEALS, JANUARY 2021–DECEMBER 2024 384 TABLE 489 QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024 384 _ FIGURE 1 RESPIRATORY DIAGNOSTICS MARKET: MARKET & REGIONAL SPREAD 34 FIGURE 2 RESPIRATORY DIAGNOSTICS MARKET: YEARS CONSIDERED 35 FIGURE 3 RESEARCH DESIGN 38 FIGURE 4 RESPIRATORY DIAGNOSTICS MARKET: KEY PRIMARY SOURCES 40 FIGURE 5 RESPIRATORY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 41 FIGURE 6 RESPIRATORY DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS 42 FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 42 FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 43 FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 43 FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44 FIGURE 11 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. (2023) 45 FIGURE 12 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2023) 46 FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET: TOP-DOWN APPROACH 47 FIGURE 14 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48 FIGURE 15 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 48 FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY 49 FIGURE 17 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2030 (USD MILLION) 52 FIGURE 18 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2030 (USD MILLION) 53 FIGURE 19 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2024 VS. 2030 (USD MILLION) 53 FIGURE 20 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2024 VS. 2030 (USD MILLION) 54 FIGURE 21 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 54 FIGURE 22 GEOGRAPHIC SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET 55 FIGURE 23 RISING PREVALENCE OF RESPIRATORY DISEASES TO PROPEL MARKET 56 FIGURE 24 INSTRUMENTS & DEVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA (2023) 57 FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 58 FIGURE 26 INDIA TO GROW AT HIGHEST GROWTH RATE DURING FORECAST PERIOD 58 FIGURE 27 RESPIRATORY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59 FIGURE 28 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DALY FOR INDIVIDUALS IN AUSTRALIA, BY AGE (2023) 60 FIGURE 29 GLOBAL GERIATRIC POPULATION, BY REGION 61 FIGURE 30 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70 FIGURE 31 NUMBER OF PATENTS PUBLISHED, JANUARY 2014–DECEMBER 2024 80 FIGURE 32 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR RESPIRATORY DIAGNOSTICS DEVICES (JANUARY 2014– DECEMBER 2024) 80 FIGURE 33 TOP PATENT APPLICANTS, BY JURISDICTION, JANUARY 2014−DECEMBER 2024 81 FIGURE 34 AVERAGE SELLING PRICE OF SPIROMETERS, BY KEY PLAYER (2024) 84 FIGURE 35 AVERAGE SELLING PRICE OF PEAK FLOWMETERS, BY KEY PLAYER (2024) 84 FIGURE 36 RESPIRATORY DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 86 FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES 87 FIGURE 38 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 88 FIGURE 39 RESPIRATORY DIAGNOSTICS MARKET: ADJACENT MARKETS 90 FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 91 FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 95 FIGURE 42 RESPIRATORY DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96 FIGURE 43 RESPIRATORY DIAGNOSTICS MARKET: NUMBER OF DEALS, 2020–2024 97 FIGURE 44 RESPIRATORY DIAGNOSTICS MARKET: IMPACT OF AI/GEN AI 99 FIGURE 45 RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 167 FIGURE 46 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 169 FIGURE 47 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 216 FIGURE 48 RESPIRATORY DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2019−2023 292 FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET (2023) 293 FIGURE 50 RANKING OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2023 294 FIGURE 51 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 296 FIGURE 52 RESPIRATORY DIAGNOSTICS MARKET: COMPANY FOOTPRINT 297 FIGURE 53 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 304 FIGURE 54 RESPIRATORY DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 307 FIGURE 55 R&D EXPENDITURE OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2022−2024 308 FIGURE 56 EV/EBITDA OF KEY VENDORS 308 FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 309 FIGURE 58 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 314 FIGURE 59 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 320 FIGURE 60 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 326 FIGURE 61 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 329 FIGURE 62 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 334 FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 342 FIGURE 64 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 347 FIGURE 65 REVVITY, INC.: COMPANY SNAPSHOT (2023) 350 FIGURE 66 SEEGENE INC.: COMPANY SNAPSHOT (2023) 353 FIGURE 67 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023) 359 FIGURE 68 RESMED INC.: COMPANY SNAPSHOT (2024) 367 FIGURE 69 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 370 FIGURE 70 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 377 FIGURE 71 QIAGEN N.V.: COMPANY SNAPSHOT (2023) 381

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們